17 apr: Europa/luk: Finanssektoren trak kraftigt op
18 apr: USA/aktier: Største stigninger i en måned
17-04-2012 21:04:00

2nd UPDATE:Top Court Sides With Generic Drug Makers In Tactics Case

Relateret indhold
08:17 - 
Aktier/tendens: Opec-aftale kan gavne Mærsk og markedet..
08:12 - 
Novo Nordisk vil afskedige 1000 medarbejdere - heraf 50..
28 sep - 
Onsdagens aktier: Pandora toppede på positiv dag for C2..
Relateret debat
08:37 - 
Yes. Der kommer mere
08:37 - 
Novo har ansat så mange de sidste 4-5 år, at der unødve..
08:36 - 
Sundt at klippe navlestrengen. Når eet vindue lukker åb..

--Justices give generics new legal tool against brand rivals

--Sun unit wins case, calls ruling important for generic drug makers

--Case involved Novo Nordisk patent for diabetes drug Prandin

(Updates with comment from Novo in 12th paragraph, additional background.)

By Brent Kendall

Of DOW JONES NEWSWIRES

WASHINGTON -(Dow Jones)- The U.S. Supreme Court handed a victory to generic drug companies Tuesday, ruling they can file certain legal counterclaims against brand-drug companies in an effort to get their cheaper copycat medicines on the market.

The court, in an opinion written by Justice Elena Kagan, ruled unanimously that generic drug makers should be allowed to challenge the way brand-name manufacturers describe their patents to the Food and Drug Administration.

The decision overturned an appeals court ruling that said generic makers can't bring those legal claims against brand rivals.

The generics argued that their brand rivals, if left unchecked, can describe their patents broadly in FDA submissions as a way to shut out possible generic competition, even for unpatented uses of a drug. The Obama administration supported those arguments.

Brand drug companies said allowing the counterclaims could lead to costly litigation and undermine patent protection for innovative drugs that are costly to develop.

The controversy arises when the FDA considers a drug maker's application to market a generic drug. As part of that process, the agency considers whether the proposed generic will infringe a branded drug's patents. To determine infringement, the FDA relies on use codes submitted by brand companies that describe the scope of their patents. The agency does not independently verify the accuracy of companies' patent submissions.

As Kagan noted, "the breadth of the use code may make the difference between approval and denial of a generic company's application."

At issue was an appeal by Caraco Pharmaceutical Laboratories, a unit of Sun Pharmaceutical Industries Ltd. (524715.BY), which is seeking to introduce a generic version of Novo Nordisk A/S's (NVO, NOVO-B.KO) diabetes drug Prandin.

One Novo Nordisk patent on the drug compound has expired, but the company holds a second patent, which doesn't expire until 2018, that involves the use of the drug in combination with another medicine.

The FDA has approved three uses for the drug. Caraco wants to introduce a generic version for the uses that aren't patented. The company said it couldn't do so because Novo Nordisk's description of its patent to the FDA was so broad that it foreclosed the agency from approving a generic version of the drug.

A Sun representative called Tuesday's ruling "a very important victory" for the company and the generic industry as a whole.

Novo said its FDA submission is correct. "We are confident that further proceedings will show Caraco's challenge to the use code narrative is meritless," James Shehan, general counsel of Novo's U.S. subsidiary, said in a statement.

In a related dispute, the two companies are fighting over the validity of the Novo patent, which a Michigan federal judge invalidated last year. That case is on appeal.

The case is Caraco Pharmaceutical Laboratories v. Novo Nordisk, 10-844.

-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com

(END) Dow Jones Newswires

April 17, 2012 15:04 ET (19:04 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
28 sep
NOVO-B
  Jeg har tidligere (blandt andet 8/8 2016) analyseret Novo og offentliggjort min beregning af, hvad..
24
27 sep
NOVO-B
Når der var en enestående mulighed. Det er lige den mulighed der er nu. Alle gode mennesker der har ..
8
25 sep
NOVO-B
Hej Larsen Synes du selv, at du kan være det indlæg bekendt - det er grebet ud i luften og stinker a..
6
23 sep
NOVO-B
Bagsværd, Denmark, 23 September 2016 - Novo Nordisk today announced the submission of a supplemental..
6
23 sep
NOVO-B
Novo's nedtur stopper desværre nok ikke før der kommer en mand med en skarp kniv i ærmet og skærer f..
4
23 sep
NOVO-B
aktien bliver ikke shortet, det er stadig reguleringer af diverse PFs hos pensions kasser og ligende..
4
28 sep
NOVO-B
Efter en start på dagen, hvor N/A startede sit sædvanlige salg af NOVO, har de resten af dagen, blot..
3
28 sep
NOVO-B
Den ser da i det mindste ud til at (indtil videre) at respektere nedtrendskanalen den ligger i, og n..
3
28 sep
NOVO-B
Novo er en aktie som placeres i den langsigtede portefølje. Jobindex og Pandora er alt for farlige t..
3
27 sep
NOVO-B
Det indlæg har du simpelthen arbejdet på og gennemarbejdet hele dagen...... 
3

Mærsk fortæller mere om ny strategi den 13. december

28-09-2016 15:49:11
A.P. Møller-Mærsk afholder sin tidligere udsatte kapitalmarkedsdag den 13. december. Det fremgår af selskabets hjemmeside.Mærsk udsatte sin kapitalmarkedsdag på..

Mærsk og kolleger undersøges for containerkartel i Sydafrika - NY

28-09-2016 12:35:22
De sydafrikanske konkurrencemyndigheder har indledt undersøgelser af seks af verdens største containerrederier - herunder lokale datterselskaber af A.P. Møller-..

Aktier/middag: Banker og Mærsk bidrager til C20-løft

28-09-2016 11:44:08
Efter tre dages fald er den positive stemning onsdag vendt tilbage til det danske aktiemarked, hvor en bredt funderet fremgang ved middagstid har løftet C20 Cap..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Mærsk: Line køber 14.800 nye kølecontainere
2
Bavarian ansætter ny medicinsk direktør
3
IMF slår alarm over handelsstop og lav inflation - citat
4
Danmark/Nykredit: Udbyttebetalinger er fortsat rekordhøje
5
Vestas henter ordre på 50 MW i Mongoliet - citat

Relaterede aktiekurser

Novo Nordisk B A/S 290,00 0,0% Aktiekurs uændret
Novo Nordisk A/S 43,74 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2016  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
29. september 2016 08:42:49
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20160921.1 - EUROWEB4 - 2016-09-29 08:42:49 - 2016-09-29 08:42:49 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x